LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

14.02 2.56

Buy Sell

Overview

Share price change

24h

Current

Min

13.67

Max

14.39

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.283 57.05
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+44.82% upside

Market Stats
By TradingEconomics
Market Cap	2.5B
Previous open	11.46
Previous close	14.02

News Sentiment

By Acuity

50%

153 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 mar 2026, 23:15 UTC

Major News Events

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 mar 2026, 22:36 UTC

Major News Events

Australian Government Rules Out Boots on the Ground in the Middle East

30 mar 2026, 22:13 UTC

Acquisitions, Mergers, Takeovers

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 mar 2026, 21:00 UTC

Earnings

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 mar 2026, 20:15 UTC

Major News Events

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 mar 2026, 23:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 23:40 UTC

Market Talk

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 mar 2026, 23:36 UTC

Market Talk

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 mar 2026, 23:12 UTC

Market Talk

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 mar 2026, 22:49 UTC

Market Talk

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 mar 2026, 22:44 UTC

Market Talk

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 mar 2026, 22:43 UTC

Market Talk

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 mar 2026, 22:42 UTC

Market Talk

South32 Should Go for Growth, Says New Bull -- Market Talk

30 mar 2026, 22:18 UTC

Market Talk

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 mar 2026, 22:05 UTC

Market Talk

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 mar 2026, 21:58 UTC

Acquisitions, Mergers, Takeovers

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 mar 2026, 21:38 UTC

Acquisitions, Mergers, Takeovers

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 mar 2026, 21:36 UTC

Acquisitions, Mergers, Takeovers

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 mar 2026, 21:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 mar 2026, 21:25 UTC

Market Talk

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 mar 2026, 21:03 UTC

Acquisitions, Mergers, Takeovers

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 mar 2026, 20:09 UTC

Earnings

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 mar 2026, 20:00 UTC

Major News Events

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

44.82% upside

12 Months Forecast

Average 20 USD 44.82%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

153 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.